Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
By: Lucas Buyon and Aaron Neal Part of NIAID’s longstanding mission is to study the biology of pathogens with pandemic potential and support the development of medical countermeasures (MCMs) against them. MCMs broadly include any medicines, vaccines, protective equipment, or other medical supplies that can be used to diagnose, prevent, or treat diseases. The emergence
By: Yan Mardian Clinical research is a vital aspect of the healthcare industry that aims to improve patient outcomes and advance medical knowledge. One of the critical components of successful clinical research is accurate and reliable laboratory testing. However, laboratory testing can be challenging to standardize, and results can vary significantly depending on the testing
By: Aly Diana In the dynamic and ever-evolving field of healthcare, the gap between evidence-based interventions and their successful implementation can hinder the delivery of high-quality care. This is where implementation research steps in, providing valuable insights and strategies to bridge this gap. In this article, we will explore the definition of implementation research, its
1st Series: Introduction to Grant proposal writing Presentation materials from speakers can be downloaded by clicking on their presentation and name below: INSTRUCTIONS & TEMPLATE FOR GRANT PROPOSAL TRAINING & WORKSHOP SUBMISSION (Download here)
To collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
